Berinert market seen expanding on diagnosis gains and higher healthcare spending
The Business Research Company says the global Berinert market is set for continued growth through 2030 as hereditary angioedema diagnosis improves, healthcare spending rises and treatment access widens. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.
Why it matters: - Berinert is a plasma-derived C1 esterase inhibitor used to treat hereditary angioedema, a rare disorder that can trigger severe swelling attacks, including airway swelling. - The market matters because faster diagnosis and broader access to specialty treatment can improve safety for patients facing acute attacks. - The Business Research Company’s latest report says the Berinert market has room to expand through 2030 and beyond as rare-disease care improves.
What happened: - The Business Research Company published its Berinert Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 2, 2026. - The report projects continued market growth driven by genetic screening, expanding rare-disease centers, more plasma fractionation capacity and wider patient access programs. - The report also highlights rising diagnosis rates, broader use of plasma-derived therapies, hospital-based management of acute hereditary angioedema episodes and more emphasis on rapid on-demand treatment. - The report covers market dynamics in North America, Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - Download a free sample of the Berinert market report. - View the full Berinert market report.
The details: - Berinert is prescribed to replace deficient or malfunctioning C1 esterase inhibitor protein in patients with hereditary angioedema. - The therapy helps regulate inflammation and blood vessel permeability through the complement and contact systems. - The report ties market growth to the increasing occurrence of genetic disorders and better diagnostic technology. - In Australia, the National Blood Authority reported 2,788 patients with hereditary haemophilia A in 2023–2024, up from 2,681 the prior year. - The report also points to rising healthcare expenditure as a support for broader access to specialized C1 esterase inhibitor therapies. - The UK Office for National Statistics reported a 5.6% nominal rise in total healthcare expenditure in 2023, a 0.9% increase compared with 2022. - An aging population is another demand driver because older adults are more likely to need ongoing healthcare support. - The UK Parliament’s House of Commons Library said 12.7 million people in the UK were aged 65 or older in 2022, equal to 19% of the population. - That figure is projected to reach 22.1 million, or 27%, by 2072. - In 2025, North America held the largest share of the Berinert market. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.
Between the lines: - The report suggests the Berinert market is being shaped less by a single product shift and more by a broader structural change in rare-disease care. - More screening and better diagnosis can enlarge the addressable patient pool, while higher healthcare spending can improve access to a therapy that is often used in urgent settings. - Regional growth is likely to diverge because mature markets already have established infrastructure, while emerging markets are still expanding diagnosis and treatment access.
What's next: - Market growth will likely track the spread of genetic screening, rare-disease centers and hospital capacity for acute hereditary angioedema care. - Wider availability of long-term safety data could support adoption over time. - The report says future growth will also depend on patient access programs and continued expansion in plasma fractionation capacity.
The bottom line: - Berinert’s market outlook is being lifted by more diagnosis, more treatment access and higher healthcare spending, with North America leading now and Asia-Pacific positioned for the fastest growth.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
The Governance Reporter of Australia
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.